Bristol-Myers Squibb Co at Leerink Partners Global Biopharma Conference Transcript

Mar 13, 2024 / 02:00PM GMT
David Reed Risinger - Leerink Partners LLC, Research Division - Senior MD & Senior Research Analyst

Great. So good morning, everyone. My name is Dave Risinger. I cover diversified biopharmaceuticals for Leerink Partners, and it's very much my pleasure to welcome Bristol-Myers' Chief Medical Officer, Samit Hirawat. And with him in the audience are Tim Power and Janet Barth in Investor Relations. We appreciate Samit joining us, taking the time out of his busy schedule to be with us here today.

Questions and Answers:

David Reed Risinger - Leerink Partners LLC, Research Division - Senior MD & Senior Research Analyst

So I guess it'd be great to have you kick off just by framing your vision for Bristol R&D, including some of the company's most substantial R&D projects that we should be focused on. And I know there are a lot of them. But it'd be great to have you just provide an initial framework.

Samit Hirawat - Bristol-Myers Squibb Company - Executive VP & Chief Medical Officer of Drug Development

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot